Drug Type Small molecule drug |
Synonyms 2,2-chlorophenylaminophenylacetate, CAP22 |
Target |
Action inhibitors |
Mechanism APOB inhibitors(Apolipoprotein B-100 inhibitors), Cholesterol inhibitors, Glycosylation inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Complications | Clinical | - | - | |
| Atherosclerosis | Preclinical | United States | 01 May 2010 | |
| Diabetes Mellitus | Preclinical | United States | 01 May 2010 | |
| Hypercholesterolemia | Preclinical | United States | 01 May 2010 |





